Scholarlink

Background <p>An anti-interleukin (IL)‑13 antibody, lebrikizumab, has shown efficacy in the treatment of atopic dermatitis (AD). However, real‑world data on 1‑year transition of clinical and laboratory indices are limited.</p> Objectives <p>To evaluate the 48‑week transition of clinical and laboratory indices during lebrikizumab treatment in Japanese patients with moderate‑to‑severe AD, stratified by the presence or absence of prior systemic therapy.</p> Methods <p>We conducted a two‑center prospective study of 187 Japanese patients with AD treated with lebrikizumab. Clinical and laboratory indices were assessed until week 48 in systemic therapy-naive and -experienced patients.</p> Results <p>Lebrikizumab reduced total and anatomical site-specific eczema area and severity index (EASI) and the peak pruritus numerical rating scale (PP‑NRS) throughout the 48 weeks. The magnitude of decreasing head and neck EASI was slightly lower in systemic therapy-experienced patients. Week 48 achievement rates of EASI 75, EASI 90, and PP‑NRS 4 were 84%, 61.8%, and 79.3% in systemic therapy-naive patients, and 68.8%, 41.7%, and 75% in systemic therapy-experienced patients, respectively. Lebrikizumab decreased immunoglobulin E, thymus and activation-regulated chemokine, and lactate dehydrogenase throughout 48 weeks.</p> Conclusion <p>In a 48‑week real‑world practice, lebrikizumab showed favorable effectiveness for AD, with higher responses in systemic therapy-naive patients compared with systemic therapy-experienced patients, including in head and neck lesions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

48-Week Real-World Outcomes of Lebrikizumab Treatment for Atopic Dermatitis: Systemic Therapy-Naive Versus -Experienced Patients

  • 期刊论文

  • 发表日期：

    2026年4月27日

查看全文
  • Teppei Hagino,
  • Akihiko Uchiyama,
  • Hidehisa Saeki,
  • Eita Fujimoto,
  • Sei-ichiro Motegi,
  • Naoko Kanda

摘要

Background

An anti-interleukin (IL)‑13 antibody, lebrikizumab, has shown efficacy in the treatment of atopic dermatitis (AD). However, real‑world data on 1‑year transition of clinical and laboratory indices are limited.

Objectives

To evaluate the 48‑week transition of clinical and laboratory indices during lebrikizumab treatment in Japanese patients with moderate‑to‑severe AD, stratified by the presence or absence of prior systemic therapy.

Methods

We conducted a two‑center prospective study of 187 Japanese patients with AD treated with lebrikizumab. Clinical and laboratory indices were assessed until week 48 in systemic therapy-naive and -experienced patients.

Results

Lebrikizumab reduced total and anatomical site-specific eczema area and severity index (EASI) and the peak pruritus numerical rating scale (PP‑NRS) throughout the 48 weeks. The magnitude of decreasing head and neck EASI was slightly lower in systemic therapy-experienced patients. Week 48 achievement rates of EASI 75, EASI 90, and PP‑NRS 4 were 84%, 61.8%, and 79.3% in systemic therapy-naive patients, and 68.8%, 41.7%, and 75% in systemic therapy-experienced patients, respectively. Lebrikizumab decreased immunoglobulin E, thymus and activation-regulated chemokine, and lactate dehydrogenase throughout 48 weeks.

Conclusion

In a 48‑week real‑world practice, lebrikizumab showed favorable effectiveness for AD, with higher responses in systemic therapy-naive patients compared with systemic therapy-experienced patients, including in head and neck lesions.